Over-the-counter statins are worth considering in primary prevention of cardiovascular disease

Circulation

Volumn 114, Issue 12, 2006, Pages 1310-1314

  Gotto Jr , Antonio M ^a   Barter, Philip J ^b   Rye, Kerry Anne ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Olin Hall 205 ^*

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NON PRESCRIPTION DRUG; PRAVASTATIN; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY RISK; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; JAUNDICE; LIFESTYLE; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MUSCULOSKELETAL DISEASE; MYOPATHY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; UNSTABLE ANGINA PECTORIS; ARTICLE; DOSE RESPONSE; METHODOLOGY; RISK ASSESSMENT; SELF MEDICATION; UNITED STATES;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; DRUGS, NON-PRESCRIPTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRIMARY PREVENTION; RISK ASSESSMENT; SELF MEDICATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33748744716     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.552257     Document Type: Review

References (31)

1. Gotto AM Jr. The case for over-the-counter statins. Am J Cardiol. 2004;94:753-756.
2. Gotto AM Jr. Over-the-counter statins and cardiovascular disease prevention: perspectives, challenges, and opportunities. Clin Pharmacol Ther. 2005;78:213-217.
3. Reuters News Service. Merck heart drug set to go over counter in Britain. May 10, 2004.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
5. Joint Meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic & Metabolic Drugs Advisory Committee January 13-14, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4086M1.htm. Accessed May 16, 2005.
6. Goff DC, Labarthe DR, Howard G, Russell GB. Primary prevention of high blood cholesterol concentrations in the United States. Arch Intern Med. 2002;162:913-919.
7. Arnett DK Jacobs DR, Luepker RV, Blackburn H, Armstrong C, Class SA. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002. Circulation. 2005;112:3884-3891.
8. Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among U.S. adults. J Am Coll Cardiol. 2004;43:1791-1796.
9. Klingman D, Williams SA, Benner JS, Smith TW, Ahn J, O'Donnell JC. Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. Am Heart J. 2005;150:595-601.
10. Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick ML, Wassertheil-Smoller S, Kuller LH, LaCroix AZ, Langer RD, Lasser NL, Lewis CE, Limacher MC, Margolis KL, Mysiw WJ, Ockene JK, Parker LM, Perri MG, Phillips L, Prentice RL, Robbins J, Rossouw JE, Sarto GE, Schatz IJ, Snetselaar LG, Stevens VJ, Tinker LF, Trevisan M, Vitolins MZ, Anderson GL, Assaf AR, Bassford T, Beresford SA, Black HR, Brunner RL, Brzyski RG, Caan B, Chlebowski RT, Gass M, Granek I, Greenland P, Hays J, Heber D, Heiss G, Hendrix SL, Hubbell FA, Johnson KC, Kotchen JM. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:655-666.
11. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
12. Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, Zagrebelsky V, Weis S, Shapiro DR, Beere PA, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 2001;87:1074-1079.
13. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
14. Matsuzawa Y, Kita T, Mabuchi H, Matsuzaki M, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H, for the J-LIT Study Group. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients: implication of the J-LIT Study, a large scale nationwide cohort study. Circ J. 2003;67:287-294.
15. Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H, for the J-LIT Study Group. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia: primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J. 2002;66:1087-1095.
16. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J. 2004;68:860-867.
17. Late breaking clinical trials news release 13: cholesterol-lowering goes a long way in halting heart disease. Available at: http://scientificsessions. americanheart.org/portal/scientific sessions/ss. Accessed November 21, 2005.
18. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:568-573.
19. Tolman KG. The liver and lovastatin. Am J Cardiol. 2002;89:1374-1380.
20. Melin JM, Struble WE, Tipping RW, Reynolds JM, Vassil TC, Levy SJ, Petrohoy TM, Midgette P, Hemwall EL, Levine JG, Irvin JD. A Consumer Use Study of Over-The-Counter Lovastatin (CUSTOM). Am J Cardiol. 2004;94:1243-1248.
21. Quill J, Martin R. Switching prescription drugs to over the counter: willingness to buy statin over the counter is not related to risk of heart disease. BMJ. 2005;330:905-906.
22. Cohen JP, Paquette C, Cairns CP. Switching prescription drugs to over the counter. BMJ. 2005;330:39-41.
23. Lynd LD, Taylor J, Dobson R, Willison DJ. Prescription to over-the-counter deregulation in Canada: are we ready for it, or do we need to be? Can Med Assoc J. 2005;173:775-777.
24. Simvastatin over the counter. Drug Ther Bull. 2005;43:25-28.
25. Strom B. Statins and over-the-counter availability. N Engl J Med. 2005;352:1403-1405.
26. Hirschler B. Pioneering OTC cholesterol drug sells slowly in UK. Available at: http://today.reuters.com/news/newsArticleSearch.aspx?storyID= 90799+04-Jul-2005+RTRS&srch=simvastatin. Accessed July 26, 2005.
27. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, for the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
28. Rubin R. Pharmacies offer "behind the counter service." Available at: http://www.usatoday.com/news/health/2005-02-07-pharmacists_x.htm. Accessed May 15, 2005.
29. Liu D. Updated: FDA panel okays Glaxo's OTC weight loss drug Alli. Available at: http://www.foodconsumer.org/777/8/ FDA_panel_okays_Glaxo_s_OTC_weight_loss_diet_pill_Alli.shtml. Accessed February 27, 2006.
30. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-161.
31. FDA Advisory Committee Briefing Document. Orlistat 60 mg capsules NDA 21-887. Available at: www.fda.gov/ohrms/dockets/ac/06/briefing/2006- 4201B1_01_GSK-Brief.pdf. Accessed February 27, 2006.